Context: Osteopathic manipulative treatment (OMT) has been studied in patients with various respiratory diseases. However, to the authors' knowledge, no studies have assessed the efficacy of OMT in patients with cystic fibrosis (CF).
in the Elderly 8 revealed shorter duration of intravenous antibiotics, shorter length of stay, and fewer deaths and respiratory failures in patients who received OMT compared with those who received conventional inpatient treatment only. Finally, a recent systematic review 9 of the literature revealed that there was a lack of rigorous, welldesigned reported trials on OMT for pediatric conditions (including asthma, bronchiolitis, and sleep apnea).
Given this lack of research, we sought to evaluate whether OMT would be beneficial in patients with CF. In the present study, we evaluated the effect of OMT in patients with CF who were admitted to the hospital for pulmonary exacerbations. We hypothesized that OMT combined with standard therapy would be more effective than standard therapy alone in improving the pulmonary function and patient perceptions of breathing in CF inpatients with pulmonary exacerbations.
Methods

Participants
The present single-blind randomized controlled trial was conducted at Nationwide Children's Hospital in Columbus, Ohio. Included in the study were patients aged 18
to 50 years admitted to the hospital with a primary diag- Questionnaire completed by inpatients with pulmonary exacerbations of cystic fibrosis before and after receiving osteopathic manipulative treatment or sham therapy (N=33). 
Results
A total of 36 patients were enrolled in the study. Two patients (1 from each study group) declined to continue the study after 2 days, and 1 patient from the OMT group
Outcome Measures
The primary outcome measure was change in FEV 1 % predicted, (FEV 1 % predicted on the final day of intervention − FEV 1 % predicted on day 1). Percent predictions were based on standards from the Third National Health and Nutrition Examination. 11 Secondary outcome measures included changes from day 1 to the last day of intervention in other spirometry measures, weight, mean temperature, mean heart rate, mean pulse oximetry, blood pressure, and mean respiratory rate. Other secondary outcomes included questionnaire assessments of change in overall breathing quality, pain level, and anxiety level.
Statistical Analysis
Changes in mean vital signs were calculated by adding all recorded vital signs from day 1 and the final day of intervention individually, calculating the arithmetic the OMT group had a larger pre-to posttreatment mean decrease in temperature than the sham therapy group, this difference was not statistically significant (P=.084).
There were no statistically significant between-group differences in pre-to posttreatment mean changes in the other vital signs or in weight.
Participants in both the OMT and sham therapy groups exhibited improvement in pulmonary function.
At baseline (day 1), no differences in spirometric meawas discharged before treatment day 4. Therefore, 33 patients completed the study (Figure 2 Abbreviations: FEF 25%-75% , forced expiratory flow at 25% to 75% of vital capacity effort; FEV 1 , forced expiratory volume in the first second of expiration (% predicted); FVC, forced vital capacity. 
Discussion
To our knowledge, the current single-blind randomized controlled trial is the first to report on the effects of OMT sures were found between the 2 groups (data not shown).
Changes in spirometry measurements in the OMT and sham therapy groups are shown in Table 2 . The improvement in FEV 1 % was not significantly different between the OMT and sham therapy groups (t= −0.29, P=.977).
Analysis of other spirometric data similarly showed no statistically significant differences (data not shown). of the study than at the beginning, compared with half of the participants in the sham therapy group (8 of 16). Although this assessment was subjective, it does support the possibility that a benefit of OMT was masked by the standard CF therapy or not measured by conventional spirometry. A sham therapy protocol similar to the one used in the present study has been reported to successfully mask OMT group assignment in at least 1 other study. 13 On the basis of these findings, we believe that the current study's protocol was sufficient to mask group assignment from our participants, limiting any possible placebo effect in the questionnaire responses of the OMT group.
Limitations of the current study were its small sample size, its lack of blinding of physicians administering OMT, and the potentially confounding CF treatments administered to both the OMT and sham therapy groups.
Osteopathic manipulative treatment is ideally administered in a nonstandardized fashion, with the physician using physical diagnosis to guide treatment techniques.
Our treatment protocol may have been limited by its standardized approach. Finally, our study did not use any validated quality-of-life or disease-specific patient reporting instruments. 14 
Conclusion
Although the benefit of OMT in other pulmonary diseases has been previously demonstrated, the current study did not show a benefit of OMT in CF patients, as measured using spirometry. Additional studies are needed to examine the potential benefit of OMT in the long-term outcomes of patients with CF, as well as in the quality of life for these patients. Given the substantial costs and morbidity associated with CF, uncovering tools that can prevent morbidity for these patients is an important task for researchers in this field. The current study involved a small number of patients in each group, and this sample size may have limited our ability to detect smaller differences in FEV 1
changes. In addition, the standard therapy for pulmonary exacerbation (eg, intravenous antibiotics, chest physiotherapy) given to patients in both study groups may have subsumed any benefit that OMT produced.
The lack of clinically significant improvement in spirometry observed in the current study (beyond that typically observed with standard CF therapy) could indi- Another study 12 of an asthmatic pediatric population demonstrated statistically significant improvement in peak expiratory flow rates of patients who received OMT compared with those who received sham therapy.
Given the chronic and unremitting nature of pulmonary disease in CF, it is also possible that OMT is unable to resolve the substantial dysfunction that CF propagates in the pulmonary system, especially in the setting of an exacerbation requiring hospitalization. The study by Noll et al 5 that showed worsening in air trapping in elderly patients with COPD immediately after they received OMT supports the notion that chronic, progressive pulmonary illnesses may not respond well to OMT.
All but 1 participant in the treatment group (15 of 16) identified their breathing as being better at the conclusion
